Financial PerformanceMRK's 2Q24 total revenue of $16.1B beats by ~$200M, mainly driven by continued strong performance from Keytruda and Gardasil.
Market ConfidenceThe company's pioneering efforts globally, and over the past 7-8 years in China, have positioned MRK to continue capitalizing on the significant unmet need driven by continually expanding recognition of the societal health benefits of the HPV vaccination.
Product GrowthKeytruda growth is unlikely to slow down given the expansion in both adjuvant and metastatic settings and continued global market penetration.